Clinical Trials

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

Investigators reported early MRD clearance without added toxicity in an elderly cohort.